- Home
- HTBI vs MLYS Comparison
HTBI vs MLYS Comparison
Compare HTBI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- MLYS
- Stock Information
- Founded
- HTBI 1926
- MLYS 2019
- Country
- HTBI United States
- MLYS United States
- Employees
- HTBI N/A
- MLYS N/A
- Industry
- HTBI Savings Institutions
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HTBI Finance
- MLYS Health Care
- Exchange
- HTBI Nasdaq
- MLYS Nasdaq
- Market Cap
- HTBI 661.4M
- MLYS 590.3M
- IPO Year
- HTBI 2012
- MLYS 2023
- Fundamental
- Price
- HTBI $37.34
- MLYS $11.48
- Analyst Decision
- HTBI Buy
- MLYS Strong Buy
- Analyst Count
- HTBI 4
- MLYS 2
- Target Price
- HTBI $37.67
- MLYS $30.00
- AVG Volume (30 Days)
- HTBI 54.4K
- MLYS 229.8K
- Earning Date
- HTBI 10-24-2024
- MLYS 11-11-2024
- Dividend Yield
- HTBI 1.28%
- MLYS N/A
- EPS Growth
- HTBI 14.18
- MLYS N/A
- EPS
- HTBI 3.52
- MLYS N/A
- Revenue
- HTBI $187,440,000.00
- MLYS N/A
- Revenue This Year
- HTBI N/A
- MLYS N/A
- Revenue Next Year
- HTBI N/A
- MLYS N/A
- P/E Ratio
- HTBI $10.62
- MLYS N/A
- Revenue Growth
- HTBI 2.84
- MLYS N/A
- 52 Week Low
- HTBI $22.31
- MLYS $5.85
- 52 Week High
- HTBI $38.62
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- HTBI 62.42
- MLYS 35.00
- Support Level
- HTBI $36.98
- MLYS $13.70
- Resistance Level
- HTBI $38.60
- MLYS $15.04
- Average True Range (ATR)
- HTBI 1.14
- MLYS 0.89
- MACD
- HTBI 0.37
- MLYS -0.30
- Stochastic Oscillator
- HTBI 79.87
- MLYS 2.08
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.